Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).